Anti-Human B7-1/CD80 Reference Antibody (Galiximab, RUO) (HW630016)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HW630016
Description	Galiximab (HW630016) is a research-grade recombinant antibody targeting CD80. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Chimeric
Isotype	IgG1-lambda
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	CD80, BB1, T-lymphocyte activation antigen CD80, CD28LG, B7, CD28LG1, LAB7, Activation B7-1 antigen, CTLA-4 counter-receptor B7.1
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P33681
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	IDEC-114, 357613-77-5
Background	T-lymphocyte activation antigen CD80 (B7-1) is a ~33 kDa protein. Costimulatory molecule that belongs to the immunoglobulin superfamily that plays an important role in T-lymphocyte activation. Acts as the primary auxiliary signal augmenting the MHC/TCR signal in naive T-cells by acting as a ligand for the CD28 receptor which is constitutively expressed on the cell surface of T-cells. In turn, activates different signaling pathways such as NF-kappa-B or MAPK leading to the production of different cytokines. Also acts as an inhibitor of T-cell activation by acting as a ligand for CTLA4, a decoy receptor, thereby blocking CD28-mediated T-cell priming. In addition, CD28/CD80 costimulatory signal stimulates glucose metabolism and ATP synthesis of T-cells by activating the PI3K/Akt signaling pathway. 1. Lu, B. et al. (2024) Acta pharmacologica Sinica 45, 1214-1223. PMID: 38467718 2. Collins, AV. et al. (2002) Immunity 17, 201-10. PMID: 12196291 3. Boulougouris, G. et al. (1999) Journal of immunology (Baltimore, Md. : 1950) 163, 1809-16. PMID: 10438913 4. Vandenborre, K. et al. (1999) Immunology 98, 413-21. PMID: 10583602 5. Stamper, CC. et al. (2001) Nature 410, 608-11. PMID: 11279502 6. Frauwirth, KA. et al. (2002) Immunity 16, 769-77. PMID: 12121659 7. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

Detects Human CD80/B7-1 in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Research Grade Galiximab.

References

Datasheet

Anti-Human B7-1/CD80 Reference Antibody (Galiximab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Recombinant Proteins

Antibodies

Assay Kits

Anti-Human B7-1/CD80 Reference Antibody (Galiximab, RUO) (HW630016)

Overview

Images

References

Datasheet

SDS

Quick access

Contact Us